Browse by category

Metabolic and bariatric surgery (MBS) reduces the risk of obesity-related cancer regardless of sex and age, according to a large Nordic registry study led by researchers at Karolinska Institutet. The results strengthen knowledge about the cancer-preventive effects of MBS for several cancers linked to obesity. "We found that the reduction in cancer risk after obesity surgery was similar across age groups and between women and men, suggesting that the long-term health benefits

Medtech giants, Medtronic and Stryker, have announced strategic investments in Cornerstone Robotics and CMR Surgical (CMR), respectively, as the companies seek to consolidate their positions in the robotic surgery market. Cornerstone Robotics' Sentire surgical system In early September, Medtronic revealed they had signed a strategic partnership with Cornerstone Robotics, in which Medtronic made an approximately $700 million investment includes rights to distribute Cornerstone

According to Professor Ahmed Ahmed, President of the British Obesity and Metabolic Specialist Society, robotic metabolic and bariatric surgery (rMBS) in the UK is still in the early stage of adoption. He said that there are several reasons why the speciality has been slower to adopt this technology compared with other surgical specialities such as urology, thoracic or colorectal. Ahmed Ahmed “I believe one of the reasons is so far there is no clear benefit of rMBS over the mo

Minister of Health (MoH) of Kuwait has issued new standards for regulating metabolic bariatric surgeries (MBS) and non-surgical interventional procedures in public and private healthcare facilities. The Ministry has established a comprehensive regulatory framework based on clear standards covering healthcare facilities, medical practitioners, patient selection and assessment, follow-up procedures, and monitoring of outcomes and complications. The standards take effect immedia

At the recent IFSO-EC meeting in Malaga, Spain, Medtronic hosted a fascinating lunch time symposium tiled, ‘A new era in robotic vessel sealing’ featured several presentations and a panel discussion on Medtronic's Ligasure vessel sealing technology, covering its technical underpinnings, clinical applications and recent integration into the Hugo RAS robotic surgery platform. Hugo RAS Ligasure Maryland In the first presentation by Dr Bruce Dunne, Senior Distinguished Engineer,

GT Metabolic Solutions has received CE certification (CE Mark) under the EU Medical Device Regulation (EU MDR) that enables commercialisation of the GT Metabolic Magnet System across the European Economic Area (EEA). GT Metabolic achieved successful review and certification of the GT Metabolic Magnet System for side-to-side enteroenterostomy (40mm, 50mm Magnets; throughout the small bowel) and gastroenterostomy (60mm, 70mm Magnets; stomach to small bowel), the first integrate

Metabolic and bariatric surgery (MBS) for teens with severe obesity is cost-effective over ten years, according to an analysis from Ann & Robert H Lurie Children's Hospital of Chicago, IL. While long-term clinical benefits of weight-loss surgery for eligible teens have been well established, and it is recommended by the American Academy of Pediatrics, insurance coverage has been limited and few teens can take advantage of the surgery. This study strengthens the case for insur

A novel PET imaging framework reveals that bariatric surgery impacts not only body weight, but also the metabolic function of multiple organs. These PET-derived insights into organ-level responses to surgery could support more precise treatment monitoring and personalized metabolic care, according to a study, ‘Evaluation of organic metabolic profiling alternation assessed by [18F]FDG PET/CT in obese patients before and after bariatric surgery’, presented at the Society of Nu

Results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes, have revealed that people with severe obesity on the highest dose (12mg) lost on average 30% of their body weight over two years. In addition, at 80 weeks, all doses of retatrutide (4mg, 9mg and 12mg) met the primary and key secondary endpoints for obesity, delivering clinicall

The ForePass endoscopic metabolic bypass platform reproduced insulin sensitivity levels observed following biliopancreatic diversion (BPD) while substantially outperforming semaglutide (Ozempic/Wegovy) in weight control in a randomised preclinical study, according to a study led by Professor Ivo Boskoski, Professor of Digestive Endoscopy at Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Rome, Lazio, Italy. ForePass endoscopic metabolic bypass platform